Quarterly report · Q1
4543.TEDINET S100RML8
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥215.3bn | 2023-04-01 → 2023-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥820.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥197.3bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥29.6bn | 2023-04-01 → 2023-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥30.4bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥29.8bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥116.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥29.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥22.5bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥22.4bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥22.5bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥22.4bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.67T | at 2023-06-30 | Cons. | Assets IFRS |
| Total assets | ¥1.60T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.58T | at 2022-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥468.1bn | at 2023-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥491.2bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.20T | at 2023-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.12T | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.20T | at 2023-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.11T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.12T | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥160.1bn | at 2023-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥209.6bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥11.4bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥117.5bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥23.4bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥19.3bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥59.1bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥16.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥27.5bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥86.6bn | 2022-04-01 → 2023-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥14.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥30.28 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥119 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥29.61 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥30.27 | 2023-04-01 → 2023-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥118.95 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥29.6 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 72.0% | at 2023-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 69.3% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 70.5% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-06-30 | ¥62m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥1.1bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥40.9bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥5.9bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥130.6bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥26.9bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥43.7bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥2.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥215.2bn |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥35.6bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-06-30 | ¥62m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥198m |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥34.5bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥3.6bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥116.8bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥28.0bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥46.0bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥4.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥197.3bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥36.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 561
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)小 山 秀 明 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)渡 辺 雄 一 | |
| Cpa3 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)松 尾 洋 孝 | |
| Number of submission | FilingDateInstant | 1 | |
| Revenue IFRS (5-year summary) | Prior1YTDDuration | 197340000000 | JPY |
| Revenue IFRS (5-year summary) | CurrentYTDDuration | 215252000000 | JPY |
| Revenue IFRS (5-year summary) | Prior1YearDuration | 820209000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior1YTDDuration | 29667000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | CurrentYTDDuration | 29804000000 | JPY |
| Profit loss before tax IFRS (5-year summary) | Prior1YearDuration | 116137000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior1YTDDuration | 22398000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | CurrentYTDDuration | 22549000000 | JPY |
| Profit loss attributable to owners of parent IFRS (5-year summary) | Prior1YearDuration | 89325000000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | Prior1YTDDuration | 117743000000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | CurrentYTDDuration | 107172000000 | JPY |
| Comprehensive income attributable to owners of parent IFRS (5-year summary) | Prior1YearDuration | 176415000000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | Prior1QuarterInstant | 1116514000000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | CurrentQuarterInstant | 1202660000000 | JPY |
| Equity attributable to owners of parent IFRS (5-year summary) | Prior1YearInstant | 1111063000000 | JPY |
| Total assets IFRS (5-year summary) | Prior1QuarterInstant | 1583371000000 | JPY |
| Total assets IFRS (5-year summary) | CurrentQuarterInstant | 1670798000000 | JPY |
| Total assets IFRS (5-year summary) | Prior1YearInstant | 1602225000000 | JPY |
| Basic earnings loss per share IFRS (5-year summary) | Prior1YTDDuration | 29.61 | |
| Basic earnings loss per share IFRS (5-year summary) | CurrentYTDDuration | 30.28 | |
| Basic earnings loss per share IFRS (5-year summary) | Prior1YearDuration | 119.00 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior1YTDDuration | 29.60 | |
| Diluted earnings loss per share IFRS (5-year summary) | CurrentYTDDuration | 30.27 | |
| Diluted earnings loss per share IFRS (5-year summary) | Prior1YearDuration | 118.95 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior1QuarterInstant | 0.705 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | CurrentQuarterInstant | 0.720 | |
| Ratio of owners equity to gross assets IFRS (5-year summary) | Prior1YearInstant | 0.693 | |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior1YTDDuration | 23361000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | CurrentYTDDuration | 11431000000 | JPY |
| Cash flows from used in operating activities IFRS (5-year summary) | Prior1YearDuration | 117536000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior1YTDDuration | -16122000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | CurrentYTDDuration | -19314000000 | JPY |
| Cash flows from used in investing activities IFRS (5-year summary) | Prior1YearDuration | -59121000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior1YTDDuration | -14845000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | CurrentYTDDuration | -27524000000 | JPY |
| Cash flows from used in financing activities IFRS (5-year summary) | Prior1YearDuration | -86559000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior1QuarterInstant | 209566000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | CurrentQuarterInstant | 160052000000 | JPY |
| Cash and cash equivalents IFRS (5-year summary) | Prior1YearInstant | 187322000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 747682540 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 747682540 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 747682540 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 747682540 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |